Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Alfredo Corell's insight:
No comment yet.
Sign up to comment
Scoop.it!
Researchers have deployed a potential new weapon against HIV – a combination therapy that targets HIV-infected cells that standard therapies cannot kill.
Alfredo Corell's insight:
Author Summary
Antiretroviral therapy (ART) improves the quality of life for HIV infected individuals. However, ART is currently a lifelong commitment because HIV persists during treatment despite being suppressed below detection. If therapy is stopped, the HIV reappears. A concerted effort is ongoing to develop new eradication therapies to prevent virus rebound, but there are challenges to be overcome. Our work is a major step forward in this process. We measured persistent HIV throughout the body during ART using bone marrow/liver/thymus (BLT) humanized mice, a model validated to study HIV persistence. HIV infected BLT mice were treated with tenofovir, emtricitabine and raltegravir. Despite documented tissue penetration by these drugs, we found that HIV expression persists in cells isolated from all the tissues analyzed (bone marrow, thymus, spleen, lymph nodes, liver, lung, intestines and peripheral blood cells). We therefore complemented ART with an immunotoxin that specifically kills HIV expressing cells while leaving other cells untouched. Our results demonstrate a dramatic reduction in persistent HIV throughout the body resulting from the killing of virus producing cells. Thus, our study provides new insights into the locations of HIV persistence during ART and a demonstration that persistent HIV can be successfully targeted inside the body. Link to PLOs journal: http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1003872
Scoop.it!
Over the past decade, scientists have made incredible strides in the field of HIV research, but a cure for the human immunodeficiency virus has still eluded scientists.
Alfredo Corell's insight:
These findings mean that scientists have many more proviruses to kill in order to fully cure an individual of HIV. However, Siliciano hopes his research will dissuade patients from entering into clinical trials testing a “shock and kill” approach to curing the virus, which involves activating many of the body’s T cells to force the proviruses to activate. Since the size of the provirus reservoir is so large, Siliciano said this technique could lead to major damage in the body. The paper in "Cell": http://www.cell.com/abstract/S0092-8674(13)01157-4 ;
Scoop.it!
AIDS is constellation disorder from HIV (human immunodeficiency virus) infection. HIV is retrovirus.
|
Scoop.it!
En la historia de la lucha contra el sida, tener una enfermedad adicional a la infección por el VIH a veces depara sorpresas. Lo hizo en el caso de Timothy Brown, el famoso pacient
Alfredo Corell's insight:
Videoentrevista al autor del articulo: Artículo en el Journal of Clinical Investigation:
Scoop.it!
RedOrbit
Alfredo Corell's insight:
Both patients had been suffering from the blood cancer Hodgkin’s lymphoma, and after other cancer treatments had proven unsuccessful, the doctors transplanted healthy bone marrow into the patients. The hope was the transplant would help purge cancerous blood cells in favor of healthy cells, but the dangerous procedure involved a weakening of the immune system and carried with it a 15 to 20 percent chance of death.
Scoop.it!
Robert A. Weinberg (Daniel K. Ludwig Professor for Cancer Research; Member, Whitehead Institute) has earned some of the top honors in his field. Most recently, he won the 2006 Landon-AACR Prize for Basic and Translational Cancer Research. He is also a 1997 National Medal of Science awardee. Weinberg’s laboratory discovered the first human oncogene and the first tumor suppressor gene. Today, much of his research focuses on new models of breast cancer development including the stages of tumor invasiveness and metastasis. He earned his Ph.D. in biology from MIT in 1969, and was one of the Founding Members of the MIT Center for Cancer Research in 1973. He was appointed a professor at MIT in 1982, the same year he joined the Whitehead Institute. Weinberg was named American Cancer Society Research Professor in 1985 and received the Daniel K. Ludwig Professorship for Cancer Research in 1997. He is a member of the National Academy of Sciences and the Institute of Medicine.
Alfredo Corell's insight:
It´s a 2008 video, but still most of the information is updated, and well explained
|
